Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Graft-versus-host disease

D Bron1

  • 1Institut Jules Bordet, Free University of Brussels, Belgium.

Current Opinion in Oncology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Graft-versus-host disease (GVHD) remains a significant complication after bone marrow transplants, despite current drug combinations. New strategies like T-cell depletion and anticytokine therapies offer improved treatment options for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polypoid colon mucosa in a leukemia patient.

Acta gastro-enterologica Belgica·2022
Same author

Aviation Cardiology.

European heart journal·2019
Same author

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2018
Same author

[Malignant or benign hyperleukocytosis ?]

Revue medicale de Bruxelles·2018
Same author

Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

[Diagnostic approach of an IgM monoclonal gammopathy and clinical importance of gene MYD88 L265P mutation].

Revue medicale de Bruxelles·2018

Area of Science:

  • Immunology
  • Hematology
  • Transplantation Medicine

Background:

  • Graft-versus-host disease (GVHD) is a major complication following allogeneic bone marrow transplantation, particularly from unrelated or mismatched donors.
  • While drug combinations (methotrexate, cyclosporin A, prednisone) reduce GVHD incidence to 20-30%, it still affects up to 90% of patients.
  • GVHD is a two-step process involving cytotoxic T cell activation and subsequent cytokine release.

Purpose of the Study:

  • To review current understanding of graft-versus-host disease (GVHD) mechanisms.
  • To discuss recent advancements in GVHD treatment modalities.
  • To highlight emerging therapeutic strategies for managing GVHD post-transplantation.

Main Methods:

  • Literature review of recent studies on GVHD pathogenesis and treatment.

Related Experiment Videos

  • Analysis of novel immunosuppressive agents.
  • Evaluation of T-cell depletion techniques and anticytokine monoclonal antibodies.

    • Main Results:

    • Established drug combinations partially control GVHD but do not eliminate the risk.
    • GVHD pathophysiology involves T cell activation and cytokine-mediated damage.
    • Emerging therapies show promise in mitigating GVHD severity and incidence.

    Conclusions:

    • Despite advances, GVHD remains a critical challenge in allogeneic bone marrow transplantation.
    • Targeting T cell activation and cytokine pathways represents a promising therapeutic direction.
    • Continued research into novel immunosuppressors and immunomodulatory agents is essential for improving transplant outcomes.